Clinical trials: Risk of Venous Thrombosis
Cerebral Stroke, Thrombosis, Deep Vein
A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement Surgery
To characterize and analyze the number, type and incidence of adverse events/suspected adverse drug reactions in patients treated with Apixaban, according to therapeutic indications approved in Mexico.
- Conditions
- Cerebral Stroke, Thrombosis, Deep Vein, Pulmonary Embolism
- Trial name
- NCT03804125
- Sponsor
- Pfizer
Venous Thromboembolism, Deep-Vein Thrombosis
Pro-coagulant Markers and Anticoagulant Failure in Cancer Patients at Risk for Recurrence of Venous Thromboembolism
The presence of clots in the veins of arms and/or legs or lungs of Cancer patients decreases their quality of life, delays their treatment and may cause death.
- Conditions
- Venous Thromboembolism, Deep-Vein Thrombosis, Pulmonary Embolism, Cancer
- Trial name
- REMARK (NCT01602445)
- Where
- 5 sites in Canada
- Volunteers
- 700 people
- Sponsor
- Ottawa Hospital Research Institute
Venous Thromboembolism
High-Risk Factors for VTE Death
Study population and characteristics This retrospective cohort study initially screened 105,168 consecutive hospitalized patients at Shihezi People's Hospital from February 2022 to June 2025.
- Trial name
- NCT07767279
- Testing
- comorbidity, Respiratory Failure, Sepsis
- Where
- China
- Volunteers
- 105,168 people
- Sponsor
- China International Neuroscience Institution
Venous Thromboembolism
the Effectiveness of Different Risk Scales In Predicting VTE in Respiratory Inpatients
To compare the predictive effectiveness of the Caprini risk assessment model, the Padua risk assessment model and the VTE risk assessment in medical patients mentioned in the 2018 edition of the Guidelines for the diagnosis…
- Trial name
- NCT04963374
- Testing
- risk evolution scale
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University Third Hospital
Venous Thromboembolism, Pulmonary Embolism
A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients
Some cancer patients starting a new chemotherapy regimen are likely to develop blood clots, also known as venous thromboembolism (VTE). Blood clots can cause symptoms and can occasionally be life-threatening.
- Trial name
- PHACS (NCT00876915)
- Testing
- dalteparin injection
- Where
- 7 sites in United States, Canada
- Volunteers
- 218 people
- Sponsor
- University of Rochester
Central Line Complication
Incidence and Risk Factors of Central Line Catheter Related Thrombosis
Central venous catheters are frequently used for monitoring haemodynamic status and rapidly delivering fluid therapy during the peri- and postoperative periods.
- Trial name
- NCT03450785
- Testing
- ultrasound examination
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Seoul National University Hospital
Venous Thromboembolism
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism
Apixaban and rivaroxaban have been compared to standard therapy for treatment of acute symptomatic venous thromboembolism (VTE) in randomized controlled trials (RCTs), and are both approved by Health Canada.
- Trial name
- COBRRA (NCT03266783)
- Testing
- Apixaban, Rivaroxaban
- Where
- 19 sites in Australia, Canada and 1 more
- Volunteers
- 2,760 people
- Sponsor
- Ottawa Hospital Research Institute
Thromboembolism
Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder
CV185118 is a single dose Apixaban PK/PD study in pediatric participants. The objective of this study is primarily to study the PK/PD of Apixaban in pediatric participants at risk for thrombosis
- Trial name
- NCT01707394
- Testing
- Apixaban
- Where
- 27 sites in United States, Australia and 3 more
- Volunteers
- 49 people
- Sponsor
- Bristol-Myers Squibb
Patients Hospitalized for More Than 48 Hours, Acute Medical Illness
Incidence and Risk Factors of Venous Thrombosis of the Lower Limbs After Hospitalization in Medical Patients at Risk
In Tunisia, the available data are limited regarding the incidence of venous thrombosis of the lower limbs (TVMI) post-hospitalization, whether symptomatic or subclinical.
- Trial name
- MTE (NCT05512923)
- Where
- Tunisia
- Volunteers
- 2,000 people
- Sponsor
- University of Monastir
Cancer-associated Thrombosis, Genetic Predisposition
A New Clinic-Genetic Risk Score for Predicting Venous Thromboembolic Events in Cancer Patient
Venous thromboembolism (VTE) is a common disease in cancer patients and one of the major causes of cancer-associated mortality. Risk for developing VTE increases when cancer patients are receiving chemotherapy.
- Trial name
- ONCOTHROMB (NCT03114618)
- Where
- 9 sites in Spain
- Volunteers
- 416 people
- Sponsor
- Andres muñoz
Sleep Apnea Syndromes, Venous Thromboembolism
Sleep Apnea and Tromboembolic Disease
There is some evidence for a hypercoagulable state in sleep apnea-hipopnea syndrome (SAHS), which could play a role in the increased cardiovascular morbility and mortality.
- Trial name
- NCT00501358
- Where
- Spain
- Sponsor
- Sociedad Española de Neumología y Cirugía Torácica
Catheter Thrombosis, Catheter-Related Infections
The Central Venous Catheter Related Complications in Critically Ill Patients
In this prospective clinical study, the researchers investigate the incidence of catheter-related thrombosis and catheter-related infection during indwelling central venous catheterization in critically ill patients, and analyzed…
- Conditions
- Catheter Thrombosis, Catheter-Related Infections, Central Venous Catheter Related Bloodstream Infection, Central Venous Catheter Thrombosis
- Trial name
- NCT03841240
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Zhujiang Hospital
Venous Thromboembolism
Identification of New Genetic Markers of Risk of Venous Thromboembolism Recurrence by Analyzing Whole Genome
Venous thromboembolism (VTE) is a common and potentially fatal disease. It is considered a chronic disease with a recurrence rate of 30% at 10 years. Reduce the risk of recurrence is a serious public health issue.
- Trial name
- NCT02904967
- Testing
- Extra Blood Draw
- Where
- France
- Volunteers
- 221 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Acute Leukemia, Deep Vein Thrombosis
Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study
This study evaluates the risks and experience of blood clots and bleeding in patients with blood cancers. While it is standard of care to use medications to reduce the risk of blood clots in hospitalized individuals, some…
- Conditions
- Acute Leukemia, Deep Vein Thrombosis, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma
- Trial name
- NCT05053100
- Testing
- Biospecimen Collection, Electronic Health Record Review
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Breast Reconstruction, Venous Thromboembolism
Microsurgical Breast Reconstruction & VTE
Venous thromboembolism (VTE) encompasses pulmonary embolism (PE) and deep venous thrombosis (DVT) and continues to be a major patient safety issue after reconstructive plastic surgery.
- Trial name
- NCT03031457
- Testing
- Duplex ultrasound
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Venous Thromboembolism
Explicit Assessment of Thromboembolic Risk and Prophylaxis for Medical Patients in Switzerland
Until now, no risk assessment model informing about the need of thromboprophylaxis in patients admitted for an acute medical event has been validated.
- Trial name
- NCT01277536
- Where
- 7 sites in Switzerland
- Volunteers
- 1,478 people
- Sponsor
- University Hospital, Geneva
COVID-19 Disease, Thromboembolism, Venous
Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19
The aim of this study is to verify if patients admitted to hospital in a medical division and in the intensive care unit for a COVID-19 infection are at higher risk of developing a VTE complication and if they actually present an…
- Trial name
- VTE-COVID (NCT04359212)
- Testing
- thromboprophylaxis with low-molecular-weight heparin or fondaparinux
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Quovadis Associazione
Pulmonary Embolism (Diagnosis), Venous Thromboembolism (VTE)
3D-EIT for Diagnosis and Monitoring of Pulmonary Embolism
This prospective observational study aims to validate three-dimensional electrical impedance tomography (3D-EIT) as a non-invasive bedside tool for the diagnosis and longitudinal monitoring of pulmonary embolism (PE).
- Trial name
- TIDE-PE (NCT07560293)
- Volunteers
- 115 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Pulmonary Embolism, Venous Thromboembolism
Prognostic Value of 2026 AHA/ACC Clinical Categorization in Acute Pulmonary Embolism Patients Presenting to the Emergency Department
Background: The 2026 American Heart Association/American College of Cardiology (AHA/ACC) Pulmonary Embolism Guideline (Creager et al., Circulation 2026) introduced a novel five-category (A-E) clinical classification system with…
- Conditions
- Pulmonary Embolism, Venous Thromboembolism, Acute Pulmonary Embolism
- Trial name
- APEX-2026 (NCT07805616)
- Testing
- 2026 AHA/ACC Clinical Risk Categorization
- Where
- Turkey (Türkiye)
- Volunteers
- 600 people
- Sponsor
- Marmara University Pendik Training and Research Hospital
Venous Thromboembolism
Systematic Review and Meta-Analysis of Venous Thromboembolism (VTE) Risk Assessment in Hospitalized Medical Patients
A systematic review and meta analysis will be performed of risk assessment models for Venous thromboembolism ("VTE" including pulmonary embolism "PE" and deep venous thrombosis "DVT")in hospitalized medical patients.
- Trial name
- NCT01446510
- Testing
- Application of VTE Risk Assessment
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Intermountain Health Care, Inc.